WO2020004194A1 - Composition à usage externe - Google Patents

Composition à usage externe Download PDF

Info

Publication number
WO2020004194A1
WO2020004194A1 PCT/JP2019/024353 JP2019024353W WO2020004194A1 WO 2020004194 A1 WO2020004194 A1 WO 2020004194A1 JP 2019024353 W JP2019024353 W JP 2019024353W WO 2020004194 A1 WO2020004194 A1 WO 2020004194A1
Authority
WO
WIPO (PCT)
Prior art keywords
ascorbic acid
composition
external
mass
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2019/024353
Other languages
English (en)
Japanese (ja)
Inventor
正彦 小森園
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kobayashi Pharmaceutical Co Ltd
Original Assignee
Kobayashi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobayashi Pharmaceutical Co Ltd filed Critical Kobayashi Pharmaceutical Co Ltd
Publication of WO2020004194A1 publication Critical patent/WO2020004194A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the present invention relates to an external composition containing ascorbic acids. More preferably, the present invention relates to an ascorbic acid-containing external composition in which precipitation under low-temperature storage conditions is suppressed. The present invention also relates to a method for suppressing precipitation under low-temperature storage conditions of an ascorbic acid-containing topical composition.
  • Ascorbic acid or its salt is used as an antioxidant (antioxidant) to prevent oxidation of the product itself due to its strong antioxidant effect, and also suppresses melanin production based on antioxidant effect (whitening effect) Therefore, it has been widely used for cosmetics, external medicines or quasi-drugs. Also, many ascorbic acid derivatives having improved skin permeability have been developed.
  • ascorbic acids have relatively high solubility in water, but are hardly soluble in lower alcohols such as ethanol, and furthermore hardly soluble in polyhydric alcohols such as glycerol. .
  • ascorbic acids have a problem that solubility is reduced by a solvent or a compounding component, and the ascorbic acid is easily precipitated particularly under a low temperature condition.
  • the present invention provides a method for precipitating an external composition obtained by dissolving ascorbic acid, a derivative thereof, or a salt thereof (hereinafter, also referred to as “ascorbic acids”) together with an edetate and erythritol in water. It is an object to suppress and improve storage stability. Specifically, it is an object of the present invention to provide an external composition having ascorbic acids, edetate, erythritol, and water, while suppressing precipitation under low-temperature conditions and having good storage stability. I do.
  • the present inventor has made intensive studies to solve the above-mentioned problems, and in addition to ascorbic acids, edetate, erythritol, and water, by adding a heparin-like substance, precipitation under low-temperature conditions can be prevented. It was found to be significantly suppressed and storage stability to be improved.
  • the present invention is an invention completed based on such knowledge, and has the following embodiments.
  • Topical composition (I-1) Topical composition containing the following components (A) to (E): (A) at least one selected from the group consisting of ascorbic acid, its derivatives and salts thereof, (B) edetate, (C) erythritol, (D) heparin analog and (E) water.
  • I-3) (I-1) or (I-), which contains the component (D) in a ratio of 0.5 to 500 parts by mass in total with respect to 100 parts by mass of the component (A) in the external composition.
  • composition for external use according to 2). The external composition according to any one of (I-1) to (I-3), which has a pH of 3 to 7.
  • I-5) The external composition according to any of (I-1) to (I-4), which is a liquid or semi-solid composition.
  • I-6) The composition for external use according to any of (I-1) to (I-5), which is a cosmetic, a topical medicine or a quasi-drug.
  • I-7) The composition for external use according to any one of (I-1) to (I-6), which is a composition wherein crystal precipitation during storage at 5 ° C. is suppressed.
  • (II) Method for Preventing Precipitate Formation (II-1) A method for suppressing precipitate formation of an external composition containing the following components (A), (B), (C) and (E), comprising the following (A) A method of suppressing the formation of precipitates, which comprises a step of adding and mixing the components (E) to (A), (B), (C) and (E) to coexist with the component (D): (A) at least one selected from the group consisting of ascorbic acid, its derivatives and salts thereof, (B) edetate, (C) erythritol, (D) heparin analog and (E) water.
  • (II-2) The method according to (II-1), wherein the composition for external use contains component (A) in a total amount of 0.01 to 10% by mass.
  • the component (D) is blended in a proportion of 0.5 to 500 parts by mass with respect to 100 parts by mass of the component (A) in the external composition, (II-1) or (II- The method for suppressing the formation of precipitates as described in 2).
  • (II-4) The method according to any one of (II-1) to (II-3), further comprising the step of adjusting the pH of the composition for external use to 3 to 7.
  • (II-5) The method according to any one of (II-1) to (II-4), wherein the composition is a liquid or semi-solid composition.
  • (II-6) The method according to any one of (II-1) to (II-5), wherein the composition is a cosmetic, a topical drug or a quasi-drug.
  • (II-7) The method for suppressing the formation of precipitates according to any one of (II-1) to (II-6), which is a method for suppressing crystal precipitation during storage at 5 ° C.
  • the present invention it is possible to suppress the formation of a precipitate under a low-temperature condition for an external composition containing ascorbic acids, edetate, erythritol, and water. Therefore, according to the present invention, it is possible to provide the ascorbic acid-containing composition having improved or improved storage stability at low temperatures.
  • the external composition of the present invention is characterized by containing the following components (A) to (E).
  • (a) Ascorbic acid The ascorbic acid used in the present invention may be any as long as it is used in the field of cosmetics, pharmaceuticals or quasi-drugs, particularly as a component of external preparations. Is not particularly limited.
  • L-ascorbic acid known by the common name of vitamin C can be preferably mentioned.
  • (B) Derivatives of ascorbic acid As the derivatives of ascorbic acid, as long as ascorbic acid, those used as components of external preparations for cosmetics, pharmaceuticals or quasi-drugs may be used. Although not limited, preferably, an ester derivative or an ether derivative can be used.
  • ester derivatives of ascorbic acid include phosphate esters of ascorbic acid such as L-ascorbic acid monophosphate ester, L-ascorbic acid diphosphate ester, and L-ascorbic acid triphosphate ester; L-ascorbic acid Fatty acid esters of ascorbic acid such as palmitic acid ester, L-ascorbic acid isopalmitic acid ester, L-ascorbic acid stearic acid ester, and L-ascorbic acid isostearic acid ester; L-ascorbic acid-2-sulfate; Can be.
  • phosphate esters of ascorbic acid such as L-ascorbic acid monophosphate ester, L-ascorbic acid diphosphate ester, and L-ascorbic acid triphosphate ester
  • L-ascorbic acid Fatty acid esters of ascorbic acid such as palmitic acid ester, L-ascorbic acid isopalmitic acid ester, L-as
  • ether derivative of ascorbic acid examples include alkyl ethers of ascorbic acid such as L-ascorbic acid methyl ether, L-ascorbic acid ethyl ether, L-ascorbic acid propyl ether and L-ascorbic acid butyl ether; L-ascorbic acid-2- Glucosides of ascorbic acid such as glucosides can be mentioned.
  • (C) Salts of ascorbic acid or a derivative thereof As salts of ascorbic acid or a derivative thereof, for example, alkali metal salts such as sodium and potassium; alkaline earth metal salts such as magnesium, calcium and barium; Metal salts such as polyvalent metal salts; ammonium and ammonium salts such as tricyclohexylammonium; and alkanolamine salts such as monoethanolamine, diethanolamine, triethanolamine, monoisopropanolamine, diisopropanolamine, and triisopropanolamine. be able to. Preferred are alkali metal salts such as sodium.
  • Preferred ascorbic acids include, for example, L-ascorbic acid, L-ascorbic acid phosphate, L-ascorbic acid-2-sulfate, L-ascorbic acid-2-glucoside, ascorbic acid ethyl ether, and the like. Salts.
  • L-ascorbic acid, L-ascorbic acid monophosphate, L-ascorbic acid-2 are particularly preferred from the viewpoints of high safety against skin or mucous membrane and high effect.
  • the content of ascorbic acids in the composition for external use of the present invention can be selected from the range of 0.01 to 10% by mass per 100% by mass of the total composition for external use. It is preferable that the ascorbic acid be incorporated in an amount of about 0.01% by mass or more in order to exert an antioxidant effect, and it is preferable that the ascorbic acid be incorporated in an amount of about 3% by mass or more in order to exert an effect of suppressing melanin production.
  • the content which can suitably obtain the precipitation suppressing effect by blending heparin or a similar substance described below is about 0.1% by mass or more, preferably 0.3 to 10% by mass, more preferably 1% by mass. -5% by mass.
  • Component (B): edetate The salt of edetic acid is a pharmaceutically acceptable salt, and may be any salt that is used as a component of an external preparation for cosmetics, pharmaceuticals or quasi-drugs.
  • alkali metal salts such as sodium and potassium
  • alkaline earth metal salts such as magnesium, calcium, and barium
  • metal salts such as polyvalent metal salts such as aluminum; ammonium and tricyclohexylammonium Can be mentioned.
  • alkali metal salts such as disodium edetate and tetrasodium edetate
  • alkaline earth metal salts such as calcium disodium edetate.
  • disodium edetate is disodium edetate.
  • edetates also include hydrates (hydrates) such as tetrasodium edetate tetrahydrate. Preferably, it is disodium edetate. Disodium edetate is also known as sodium edetate, sodium ethylenediaminetetraacetate, or sodium EDTA, and is used in the field of cosmetics, pharmaceuticals or quasi-drugs, as a stabilizer, sequestering agent, antioxidant, and antibacterial agent. It has been widely used as a preservative, preservative or preservative.
  • the content of the edetate in the composition for external use of the present invention can be selected and set from the range in which the compound is allowed to be incorporated into the external preparation of cosmetics, pharmaceuticals or quasi-drugs. Although not limited, it can be selected, for example, from the range of 0.01 to 0.5% by mass, preferably 0.01 to 0.3% by mass, more preferably 0.05 to 0.2% by mass.
  • Erythritol is a sugar alcohol known to have a moisturizing action and an endothermic action, and has been used as a component of an external preparation of cosmetics, pharmaceuticals or quasi-drugs for the purpose of moisturizing and improving the feeling of use. It is used for
  • the content of erythritol in the composition for external use of the present invention can be selected and set from the range in which compounding is permitted for an external preparation of cosmetics, pharmaceuticals or quasi-drugs. Although not restricted, it can be selected, for example, from the range of 0.01 to 10% by mass, preferably 0.5 to 5% by mass, more preferably 1 to 3% by mass.
  • Heparin-like substance is a component that has been known for its blood circulation promoting action, skin moisturizing action, and the like, and is a polysulfated mucopolysaccharide such as chondroitin polysulfate.
  • the monosaccharide constituting the mucopolysaccharide preferably has an average of 0.5 to 5 molecules, more preferably an average of 0.6 to 3 sulfate groups per molecule.
  • Heparin analogs also include, for example, heparin; and chondroitin polysulfates such as chondroitin sulfate D and chondroitin sulfate E.
  • a heparin-like substance (Heparinoid) listed in the Japanese Pharmacopoeia Non-Pharmaceutical Standard can be preferably used.
  • the content of the heparin-like substance in the composition for external use of the present invention can be selected and set from a range in which compounding is permitted for an external preparation of cosmetics, pharmaceuticals or quasi-drugs. Although not limited, it can be selected, for example, from the range of 0.01 to 1% by mass, preferably 0.05 to 0.5% by mass, more preferably 0.05 to 0.4% by mass.
  • the heparin-like substance is not limited, it is preferable to mix it in the range of 0.5 to 500 parts by mass with respect to 100 parts by mass of ascorbic acid (A) contained in the external composition of the present invention. It is more preferably 1 to 50 parts by mass, particularly preferably 3 to 20 parts by mass.
  • the heparin-like substance is not limited, it is preferable to mix it in the range of 10 to 3000 parts by mass with respect to 100 parts by mass of the edetate (B) incorporated in the composition for external use of the present invention. It is more preferably from 30 to 1,000 parts by mass, particularly preferably from 50 to 500 parts by mass.
  • the heparin-like substance is not limited, but is preferably added in the range of 0.5 to 100 parts by mass relative to 100 parts by mass of (C) erythritol contained in the composition for external use of the present invention. More preferably, it is 2.5 to 25 parts by mass, particularly preferably 2.5 to 20 parts by mass.
  • Component (E): Water Water is typically topical compositions (cosmetics, pharmaceuticals, quasi-drugs) depending on the application of, as long as it has a purity or purity of the extent used therein, to the extent that There is no particular limitation. Specifically, ion-exchanged water, distilled water, purified water, sterilized water and the like can be used without limitation. From the aspects of hygiene and storage stability, purified water, ion-exchanged water, and sterilized water can be suitably used. The amount of water is such that the total composition is finally brought to 100% by mass. Specifically, it can be selected and adjusted within a range in which the effect of suppressing precipitation of the present invention is exhibited without impairing the shape of the composition for external use of the present invention. Although not limited, it can be added, for example, at a ratio of 10 to 99.8% by mass, preferably 50 to 99% by mass, more preferably 70 to 95% by mass.
  • the topical composition of the present invention does not impair the storage stability (prevention of precipitation), which is the effect of the present invention, and does not impair the effect of each compounding component.
  • known additives to be added to cosmetics can be blended. Examples of such additives include bases, surfactants, thickeners, preservatives, antioxidants, chelating agents, stabilizers, stimulants, colorants, fragrances, and the like.
  • the composition for external use of the present invention does not impair the storage stability (prevention of precipitation), which is the effect of the present invention, and does not impair the effect of each compounded component in order to add other useful effects.
  • Known active ingredients added to pharmaceuticals, quasi-drugs, or cosmetics can be blended within the range.
  • active ingredients include anti-inflammatory agents, humectants, vitamins, astringents, antibacterial components, peptides or derivatives thereof, amino acids or derivatives thereof, cell activating components, anti-aging components (anti-wrinkle agents), and blood circulation promoting components. , Whitening ingredients, natural extracts, enzymes, bactericides and the like.
  • the pH of the composition for external use of the present invention is not limited, but is preferably adjusted to a range of pH 2 to 9.
  • the pH is more preferably in the range of 3 to 7.
  • the pH may be adjusted by an organic acid (citric acid, lactic acid, acetic acid, tartaric acid, malic acid, succinic acid, oxalic acid, fumaric acid, gluconic acid, aspartic acid, etc.) or a salt thereof according to a standard method, if necessary.
  • Inorganic acids hydroochloric acid, sulfuric acid, phosphoric acid, polyphosphoric acid, boric acid, etc.
  • inorganic salts sodium hydrogen carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, etc.
  • organic salts monoethanolamine, PH adjusters such as amines such as triethanolamine
  • the external composition of the present invention may be composed of the above-mentioned components (A) to (E). However, as long as the effects of the present invention are not impaired, pharmaceuticals, quasi-drugs, or cosmetics
  • the composition can be mixed with a base or carrier commonly used in the manufacture of pharmaceutical products, and, if necessary, with additives and useful components, to give an external composition for pharmaceuticals, quasi-drugs, or cosmetics.
  • the composition for external use of the present invention has a liquid or semi-solid form.
  • liquid or semi-solid means that it has a liquid or semi-solid form at least at a low temperature (5 ° C.) to a normal temperature (25 ⁇ 5 ° C.).
  • the semi-solid state means a form that flows under its own weight. Examples of those having a liquid or semi-solid form include solutions, colloid solutions (sols, suspensions and emulsions), and gels (gels).
  • the formulation is not particularly limited, and examples thereof include a liquid, a suspension, an emulsion, a cream, an ointment, a gel, a liniment, and a lotion.
  • Can be The external composition for pharmaceutical use is preferably used in the form of a liquid, emulsion, or gel, more preferably a liquid or gel.
  • composition for external use of the present invention is a quasi-drug or cosmetic
  • the form is not particularly limited, and examples thereof include a lotion, an emulsion, a cream, a serum, a hand cream, and a basic cosmetic such as a body lotion. And medicated cosmetics.
  • the method for preparing the external composition of the present invention is not particularly limited, and can be prepared according to a standard method based on the type and use (medicine, quasi-drug, cosmetic) of the external composition and its shape. Specifically, for example, the above-mentioned components (A) to (E) or, if necessary, in addition to these, various ordinary components necessary for preparing an external composition are appropriately selected and blended, and the mixture is formed by a conventional method. Can be prepared.
  • the thus-prepared external composition is filled in a container.
  • the shape of the container may be any as long as it can accommodate a liquid or semi-solid composition, and can be appropriately selected according to the form, application, and method of use (administration method).
  • examples of the container include a bottle container (a roll-on container, a bottle container having a sponge-shaped application member in a head, a jar bottle container), a pump spray container, a pump discharge container, a container for an aerosol agent, and a tube container. And the like.
  • precipitation under low-temperature conditions is significantly suppressed. For example, when stored for 2 days at 5 ° C., the generation of precipitates is suppressed as compared with an external composition not containing the component (D).
  • the application amount and usage of the external composition of the present invention to the outer skin are not particularly limited, and usually, an appropriate amount can be applied to the outer skin such as the skin several times a day, for example, by coating.
  • Examples of the use of the composition for external use of the present invention include pharmaceutical use (treatment / improvement) and skin care use, but are not particularly limited thereto.
  • the composition for external use of the present invention is used for moisturizing, anti-inflammation, care (moisturizing) of scars remaining on the skin (scars, burns, acne scars, pregnancy marks), and for the purpose of preventing keloid formation. It is preferably used.
  • the present invention relates to an external composition containing (A) ascorbic acids, (B) edetate, (C) erythritol, and (E) water as described above, which precipitates during low-temperature storage.
  • This is a method of suppressing generation of.
  • This method can be carried out by placing the components (A) to (C) of the external composition in the presence of (D) a heparin-like substance in the presence of (E).
  • Such a coexistence state can be conveniently formed by adding and blending the component (D) when producing an external composition containing the components (A) to (C) and (E).
  • the external component containing the components (A) to (C) and (E) Precipitation during low-temperature storage of the composition can be suppressed.
  • low-temperature storage refers to a static storage at a normal pressure of 5 ° C. for 2 days or more.
  • “Inhibition of precipitate formation during low-temperature storage” means that (A) ascorbic acids, (B) edetate, (C) erythritol and (E) ) Means that the formation of precipitates that can occur in the external composition containing water is suppressed by using (D) a heparin-like substance in combination.
  • the suppression includes not only the case of completely inhibiting (blocking) the generation of the precipitate but also the case of delaying the generation of the precipitate.
  • Whether or not the formation of precipitates is suppressed is determined by (A) ascorbic acids, (B) edetate, (C) erythritol, (D) heparin analog, and ( E) A composition for external use containing water (test sample) and a sample obtained by removing the (D) heparin-like substance from the test sample as a control sample were kept at least under normal pressure at 5 ° C for at least 2 days. It can be evaluated by comparing the formation of precipitates for both. When the generation of the precipitate of the test sample is suppressed as compared with the control sample, it can be determined that the method of the present invention has been performed on the test sample. In addition, instead of “storage at room temperature under 5 ° C. for 2 days or more”, the generation of precipitates in the test sample is suppressed as compared to the control sample by an accelerated test that can be regarded as equivalent conditions. In this case, it can be determined in the same manner.
  • the types of the components (A), (B), (C), (D), and (E) used in the method of the present invention, the mixing ratio thereof, and the composition for external use containing the same are (I) As described in the above, the present invention can be directly applied to the present invention.
  • Example 1 Storage stability test The components shown in Table 1 were weighed, mixed by stirring, and dissolved to prepare aqueous compositions (Examples 1 and 2, Comparative Examples 1 and 2). Each of these was filled in a transparent glass bottle (with a lid), and the test sample immediately after preparation was visually observed for the presence or absence of precipitation. Then, these were stored in a dark place at 5 ° C. for 2 days, and the presence or absence of precipitation after storage was visually observed.
  • FIG. 1 shows images of the test samples (Examples 1 and 2 and Comparative Examples 1 and 2) photographing the appearance immediately after preparation and the appearance after storage.
  • FIG. 2 shows an image of the appearance of the test sample (Example 3) after storage.
  • Example 7 Gel (pH 6.9) A gel composition having the following formulation and in which precipitation under low temperature conditions was suppressed was prepared.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Le problème décrit par la présente invention est de fournir une composition à usage externe comprenant de l'acide ascorbique ou analogue. Plus préférentiellement, le problème est de fournir une composition à usage externe comprenant de l'acide ascorbique ou analogue dont le dépôt est supprimé dans des conditions de stockage à basse température. La solution selon l'invention porte sur une composition à usage externe qui contient les constituants suivants : (A) au moins un élément choisi dans le groupe constitué par l'acide ascorbique, ses dérivés et ses sels ; (B) un sel d'acide édétique ; (C) de l'érythritol ; (D) une substance de type héparine ; et (E) de l'eau.
PCT/JP2019/024353 2018-06-28 2019-06-19 Composition à usage externe Ceased WO2020004194A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-122808 2018-06-28
JP2018122808A JP7321680B2 (ja) 2018-06-28 2018-06-28 外用組成物

Publications (1)

Publication Number Publication Date
WO2020004194A1 true WO2020004194A1 (fr) 2020-01-02

Family

ID=68987133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/024353 Ceased WO2020004194A1 (fr) 2018-06-28 2019-06-19 Composition à usage externe

Country Status (3)

Country Link
JP (1) JP7321680B2 (fr)
TW (1) TWI902663B (fr)
WO (1) WO2020004194A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022138871A1 (fr) * 2020-12-24 2022-06-30

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021059520A (ja) * 2019-10-09 2021-04-15 ロート製薬株式会社 外用組成物
JP7728228B2 (ja) * 2021-04-27 2025-08-22 久光製薬株式会社 ヘパリン類似物質含有ゲル組成物及びその粘度低下抑制方法
JP2021143205A (ja) * 2021-06-24 2021-09-24 小林製薬株式会社 ニキビの予防又は改善用の外用組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH115725A (ja) * 1997-06-13 1999-01-12 Shiseido Co Ltd 皮膚外用剤
JP2010180206A (ja) * 2009-01-09 2010-08-19 Rohto Pharmaceut Co Ltd ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩を含有する外用組成物の変色抑制方法
JP2012120441A (ja) * 2010-12-06 2012-06-28 Sunstar Inc アスコルビン酸及びその類縁体を安定配合した組成物
WO2016159186A1 (fr) * 2015-03-31 2016-10-06 小林製薬株式会社 Composition de type gel pour application externe

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH115725A (ja) * 1997-06-13 1999-01-12 Shiseido Co Ltd 皮膚外用剤
JP2010180206A (ja) * 2009-01-09 2010-08-19 Rohto Pharmaceut Co Ltd ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩を含有する外用組成物の変色抑制方法
JP2012120441A (ja) * 2010-12-06 2012-06-28 Sunstar Inc アスコルビン酸及びその類縁体を安定配合した組成物
WO2016159186A1 (fr) * 2015-03-31 2016-10-06 小林製薬株式会社 Composition de type gel pour application externe

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022138871A1 (fr) * 2020-12-24 2022-06-30
WO2022138871A1 (fr) * 2020-12-24 2022-06-30 浩志 川野 Agent d'amélioration d'une maladie cutanée

Also Published As

Publication number Publication date
TWI902663B (zh) 2025-11-01
JP2020002060A (ja) 2020-01-09
JP7321680B2 (ja) 2023-08-07
TW202000193A (zh) 2020-01-01

Similar Documents

Publication Publication Date Title
KR20150057918A (ko) 피부 미백용 조성물
WO2020004194A1 (fr) Composition à usage externe
JP6908448B2 (ja) 医薬組成物
JPH01193206A (ja) 皮膚の老化に対するアデメチオニンの用途
TWI815914B (zh) 外用組成物、析出物生成抑制方法
JP6060742B2 (ja) 外用液体組成物
TWI766912B (zh) 水性製劑
JP7359909B2 (ja) 口腔用組成物の製造方法、口腔用組成物の口腔内塗布部との密着性を向上させる方法および口腔用組成物の口腔内塗布部における滞留性を向上させる方法。
CN113679664B (zh) 白藜芦醇高分子水溶液及其制备方法
JP6871086B2 (ja) 医薬組成物
JP2023018864A (ja) ロキソプロフェン含有外用塗布剤
RU2428167C2 (ru) Препарат для наружного нанесения на кожу, обладающий повышенной стабильностью
WO2020196852A1 (fr) Formulation aqueuse
JP2008056703A (ja) 育毛用組成物
JP7628425B2 (ja) トラネキサム酸配合外用組成物
JP7190538B2 (ja) 医薬組成物
JP2006022091A (ja) 育毛用組成物
HK40045236A (en) External-use composition
JP7590833B2 (ja) 皮膚外用組成物
JP7586879B2 (ja) 医薬組成物
HK40045236B (zh) 外用组合物
JP7550014B2 (ja) 医薬組成物
JP2018065884A (ja) 外用組成物
JP2007191473A (ja) 新規な育毛用組成物
JP2024006898A (ja) 外用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19826173

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19826173

Country of ref document: EP

Kind code of ref document: A1